Drugs.com New Drug ApplicationsOriginal article
New Drug Application for Neladalkib in TKI Pre-Treated Advanced ALK-Positive NSCLC Accepted for Filing with Priority Review by the FDA
NDA FilingNeladalkibPositive
AI Analysis
Summary
Nuvalent announced that the FDA has accepted its New Drug Application for Neladalkib in TKI pre-treated advanced ALK-positive NSCLC for filing with Priority Review designation.
Outcome Details
NDA accepted for filing with Priority Review
Importance:7/10
Sentiment:
0.70
NDA FilingPriority ReviewALK-Positive NSCLCKinase Inhibitor
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on May 27, 2026 4:05 AM